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Testicular cancer: a longitudinal pilot study
on stress response symptoms and quality
of life in couples before
and after chemotherapy
Abstract Goals of work: The cur-
rent study was designed to longi-
tudinally examine stress response
symptoms (SRS) and quality of life
(QoL) in couples confronted with
disseminated testicular cancer. The
objectives were to examine couples’
patterns of adjustment over time and
possible differences in adjustment
between the patient and his partner.
Materials and methods: Couples
completed the Impact of Event Scale
and the QoL subscales physical
functioning, social functioning, and
mental health of the RAND-36 before
chemotherapy (T1), after completion
of chemotherapy (T2), and 1 year
later (T3). Results: Before chemo-
therapy 26% of the patients and 50%
of partners reported clinically ele-
vated levels of SRS. Patients reported
lower physical and social functioning
at T2 compared to T1 and T3.
Partners reported an improvement in
social functioning over the year and
no changes in physical functioning or
mental health. No relationships be-
tween patients and partners’ func-
tioning were found. One year after
diagnosis, QoL of patients and part-
ners was similar to that of reference
groups, and patients even reported
better physical functioning than the
reference group. SRS of patients and
partners were negatively related at T1,
and patients and partners’ social
functioning were positively related at
T2. Conclusions: According to
stress response levels, the period
before the start of chemotherapy was
most stressful for couples. Adjust-
ment patterns differ between testicular
cancer patients and their partners with
patients reporting lowered QoL after
completion of chemotherapy. QoL of
couples returned to normal levels
1 year after diagnosis. The effect of
disseminated testicular cancer on the
QoL of patients and their partners
seems to be temporary. A minority
may need clinical attention for severe
SRS.
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Introduction
Testicular cancer is a rare disease, although it is the most
common tumor in men aged 20–35 years. About 500 new
cases are diagnosed each year in The Netherlands [1].
Testicular cancer is distinguished into seminomas and
nonseminomas, and each type accounts for about half of
the total. Half of the men with nonseminoma are diagnosed
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Groningen, 9700 AH, The Netherlandswith disseminated disease that is treated with chemother-
apy [2]. Since the introduction of cisplatin-based chemo-
therapy in the late 1970s, up to 80% of the patients with
disseminated disease can be cured [3–5].
Chemotherapy for testicular cancer has several acute
physical side effects like nausea, fatigue, and neuropathy
[6]. On a psychological level, patients receiving chemo-
therapy have been found to report anxiety, depression, and
distress [7–10]. The partners of testicular cancer patients
receiving chemotherapy may encounter adverse sequelae
as well. Partners have to struggle with the fear of
potentially losing their significant other. Partners are the
primary source of information for family members and
friends while their husbands are admitted to the hospital. In
addition to this social task, partners often take on the
caregiver role between chemotherapy cycles. Caregiving
for cancer patients was found to negatively impact a
caregiver’s physical and mental health [11–13].
The impact of testicular cancer on younger couples
might differ from the impact on couples who face cancer at
an older age. The young couples confronted with testicular
cancer might not have been together for a substantial period
of time. This can make the relationship more vulnerable to
the stressors induced by major life events. Earlier studies
have shown that relationships of shorter duration are more
sensitive to disruption after a testicular cancer diagnosis
[14, 15], although another study did not find such a
connection [16]. Also, couples are confronted with
possible treatment-related infertility and sexual difficulties
at a time in life where partners are often focused on starting
a family. Couples may face several individual and dyadic
stressors after the diagnosis of testicular cancer, leading to
the experience of distress and lowered quality of life (QoL).
This is particularly true when chemotherapy is part of the
treatment protocol, as it is a more demanding treatment
modality than surgery alone in the case of testicular cancer.
Several prospective studies focused on dyadic adjust-
ment and functioning from cancer diagnosis in a variety of
sites, up to 1 1/2 years later [17–20]. Although both
patients and partners were reported to suffer from distress,
levels of distress did not necessarily correspond within
couples. Different patterns of distress and adjustment were
found to be associated with gender and health status. Some
studies reported that female partners were most vulnerable
because they reported higher levels of distress than female
and male patients and male partners [20–22].
One pilot study examined the course of distress and QoL
in testicular cancer patients before, during, and after
chemotherapy (complete data on ten patients). Patients
reported highest levels of distress shortly before the start of
chemotherapy. Distress and anxiety decreased over time
[23]. Another recent prospective study on a large group of
testicular cancer patients receiving chemotherapy focused
on global QoL during the first 2 years after diagnosis. A
considerable impairment in global QoL was found after
3 months. However, after 2 years 36% of patients reported
improved functioning compared to baseline [24]. At the
University Medical Center Groningen (UMCG) in The
Netherlands, a tertiairy referral center for patients with
testicular cancer, and at the University of Texas M. D.
Anderson Cancer Center, USA considerable institutional
research was done into epidemiology, short- and long-term
medical, and sexual outcomes of testicular cancer [25–28].
These cross-sectional and retrospective studies were done
on QoL of testicular survivors [29], their partners [30], and
marital and sexual satisfaction [16, 31–33]. We chose to
expand these findings by performing a prospective study,
and the findings of Trask and Fossa by including partners
in our prospective study. Patterns of stress response
symptoms (SRS) and QoL of patients and partners were
examined at three time points during the first year. SRS can
occur after a range of traumatic events, including cancer.
They involve intrusive thoughts and avoidance of thoughts
and situations that remind them of the event, and are often
studied in cancer patients [34]. Goals of the present study
were: (1) to explore differences and relationships between
patients and partners’ SRS and QoL and to relate those to
relationship aspects (duration and presence of children); (2)
to examine change over time in SRS and QoL in patients
and partners; (3) to relate earlier levels of SRS and QoL in
patients and partners to later levels; and (4) to examine
differences in QoL of patients and partners with that of a
reference group of men and women.
Materials and methods
Procedure and participants
All patients diagnosed with a disseminated nonseminoma-
tous testicular tumor who consecutively visited the UMCG
in The Netherlands for treatment between April 2001 and
March 2004 and who were married or cohabiting were
approached for this study. Only patients who received
chemotherapy and had a steady relationship (n=30) could
be included in this study. Other inclusion criteria were age
over 18 years at study entry, sufficient command of the
Dutch language, no previous treatment for cancer, and
absence of a psychiatric history. The study was introduced
to the patients and their partners after orchiectomy
(removal of the affected testicle) was performed. Couples
received a questionnaire at the following three time points:
after orchiectomy but before the start of chemotherapy
(T1), immediately after completion of chemotherapy,
which is approximately 3 months after T1 (T2), and
1 year after T1 (T3). The patients received four cycles of
cisplatin, etoposide, and bleomycin with a 3-week interval
between each cycle. Couples received a letter with
information about the objectives of the study, an informed
consent form, the questionnaires, and a prepaid return
envelope. Thirty of the 70 patients diagnosed during the
above-mentioned time period appeared to meet all of the
280inclusion criteria. They and their partners were approached
to participate in the study. Of the eligible 30 couples, 21
participated (70%). Two couples did not complete all three
measurement times, therefore, only 19 couples provided
complete data. The study was approved by the Medical
Ethics Committee of the UMCG.
Measurements
Sociodemographics: Data on the following sociodemo-
graphic variables were collected at T1: age, educational
level, employment status, presence of children, and
duration of the relationship. Highest educational level
completed was measured on a seven-point scale: primary
school [1], and lower vocational [2], lower secondary [3],
middle secondary [4], high secondary [5], higher voca-
tional degrees [6], and advanced university [7]. Employ-
ment status could be indicated as employed for wages,
housekeeping, student, unemployed, unable to work, or
retired.
SRS were measured with the Impact of Event Scale
(IES) [35, 36]. This scale (15 items) makes an inventory of
the extent to which a subject is currently occupied with an
event by measuring intrusion (intrusively experienced
ideas, images, feelings, or bad dreams about the event; 7
items) and avoidance of unpleasant feelings or memories of
the event (8 items), resulting in a total score of SRS.
Patients and partners rated the frequency of SRS with
respect to his cancer during the preceding 7days. Examples
of items include: “Any reminder brings back feelings about
it” (intrusion) and “I try to banish it from my memory.” The
IES is a valid instrument for measuring cancer-related SRS
[37, 38]. With this questionnaire, information was obtained
about the degree to which confrontation with testicular
cancer was influencing the current daily life of the
respondent. Higher scores indicate more SRS. The Dutch
version of the IES indicates a total score of more than 26 as
severe SRS, for which psychological help is recommended.
Reliability of this scale was good for patients (Cronbach’s
alpha for the different measurement times ranged from 0.82
to 0.89) and for partners (Cronbach’s alpha for the different
measurement times ranged from 0.78 to 0.93).
QoL was measured with three subscales of the RAND-
36 [39]: physical functioning (ten items), social function-
ing (two items) and mental health (five items). To avoid
statistical problems due to multiple comparisons, we chose
these three subscales as a representation of overall QoL.
The RAND-36 measures generic QoL. After recoding and
transformation, scores on the subscales could range from 0
to 100. Higher scores indicate a better QoL. Reliability of
these scales was good to very good for patients
(Cronbach’s alpha for the different measurement times
ranged from 0.67 to 0.90) and for partners (Cronbach’s
alpha for the different measurement times ranged from 0.75
to 0.92). The Dutch manual for the RAND-36 provides
reference scores. These comprised the mean scores of a
group of 691 nonselected men and 372 nonselected women
from a random representative sample of persons aged
18 years and older from the population register of a
municipality in the north of The Netherlands (number of
inhabitants=108,000). The mean age of the persons in the
total random sample was 44.1 years (range 18–89 years)
[39].
Statistical analyses
The database consisted of matched pairs of patients and
partners, making analyses on pair level possible. Paired
t tests and chi-square test were performed to examine
differences in sociodemographics between patients and
partners. Wilcoxon signed rank test (because of small
sample size) and correlations were computed to examine
differences and relationships in SRS and QoL between
patients and partners. Independent t tests were performed
for having children (yes or no) with SRS and QoL.
Pearson’s product moment correlations were calculated to
examine the relationship between duration of the relation-
ship and patients and partners’ SRS and QoL. Repeated
measures analysis of variance (ANOVA) was used to
examine change over time in functioning. Pearson’s
product moment correlations were calculated to examine
relationships between the functioning of patient and that of
the partner and between measurement times. Strong
correlation coefficients (>0.50) indicate consistency be-
tween measurement times and stable responses between
earlier and later levels of functioning. Independent t tests
were performed to compare QoL of patients and partners
with those of a reference group of men and women.
Results
Sociodemographic and treatment-related variables
Sociodemographic and treatment related variables are
reported in Table 1. Patients were older than partners (t=
−3.1, p<0.01). The mean time couples had been together
was 5.7 years. Eighteen patients were employed for wages
and 1 was a student, whereas 11 partners were employed
for wages, 4 were home-keepers and the remaining 4
partners were students (chi-square=19.0, p=0.04). Of the
21 couples, 5 had children and 14 did not. After
chemotherapy was completed (at T2), all patients were
restaged. Patients without biochemical or radiological
abnormalities were considered to have reached complete
remission (n=8). In case of proven residual disease, a
resection of residual retroperitoneal tumor mass (RRRTM)
was performed. Eleven patients underwent this surgery and
were considered to be in complete remission afterward.
281None of the 19 patients experienced a relapse during
follow-up (up to T3).
Patients’ and partners’ SRS and QoL
At T1, SRS of patients were moderately strongly and
negatively related to those of partners (r=−0.48, p<0.05).
At T2, social functioning of patients was moderately
strongly and positively related to that of partners (r=0.53,
p<0.05). At the three measurement times all other
correlations between patients’ SRS and QoL and those of
partners were low to moderate, ranging from r=0.04 to
0.34, and notstatistically significant. At T1, in two couples,
both patient and partner experienced SRS above the cut-off
point. At T2 and T3 there were no couples in which both
patient and partner experienced SRS above the cut-off
point. Wilcoxon tests showed only one significant
difference between patients and partners’ functioning. At
T2, patients reported a lower level of physical functioning
than did partners (Z=−2.6, p<0.01).
Independent t tests did not show a significant relation-
ship between having children and SRS for patients at all
measurement times, and for partners at T1 and T2. At T3
partners with children reported higher levels of SRS than
partners who did not have children (t=2.6, p=0.018). The
presence of children was unrelated to patients’ and
partners’ QoL at all measurement times. The duration of
the relationship was not significantly related to the patients’
or partner’s SRS or QoL at all measurement times and
relationships were absent to very weak.
The course of SRS and QoL over time in patients
and partners
Repeated measures ANOVA showed that the SRS of
patients fluctuated according to a quadratic trend: The
highest level was reported at T1 and after a decrease at T2,
the level was increased again somewhat at T3. Earlier
levels of SRS in patients were highly positively related to
later levels (Table 2). At T1, five of the patients (26%)
reported stress response levels above the cut-off point; at
T2, two patients (11%); and at T3, three patients (16%).
Two patients reported clinically elevated levels of stress
response levels at all measurement times. For partners the
levelofSRSdeclined,viaalineartrend.Partners’reportsof
stress response levels were moderately strongly related
between T1 and T2, strongly between T2 and T3, and the
relationship between T1 and T3 was weak (Table 2). At T1,
ten of the partners (53%) reported stress response levels
above the cut-off point, at T2, six (32%), and at T3, two
(10.5%). One partner reported clinically elevated levels of
stress response levels at all measurement times.
Lower physical functioning was reported by patients at
T2 compared to T1, but physical functioning returned to
baseline level at T3. Earlier levels of physical functioning
in patients were not significantly related to later levels, and
correlations were low. A decline in social functioning of
patients was also found at T2 compared to T1, but higher
social functioning than at baseline was found at T3. Social
functioning of patients at T1 was positively and strongly
related to functioning at T2, but the relationships between
T2–T3 and T1–T3 were low to moderate. Mental health of
patients improved over time. Mental health at T1 was
positively and strongly related to levels at T2, and weakly
to levels at T3. The relationship between mental health at
T2 and T3 was moderately strong.
For partners, no significant time effects were found for
physical functioning and mental health. Earlier levels of
physical functioning and mental health of partners were
highly and positively related to later levels. Social
functioning of partners improved over the year and was
highly positively related between T1 and T2 and between
T1 and T3. The relationship between T2 and T3 was
moderately strong. (Table 2).
QoL of patients and partners compared to that
of a reference group of men and women
At T1, patients (t=−3.4, p<0.01) and partners (t=−2.1,
p<0.05) reported better physical functioning than the
reference groups. Patients (t=2.3, p<0.05) and partners
(t=2.9, p<0.01) reported worse social functioning than the
Table 1 Descriptives of sociodemographic and treatment-related
variables
Patient Partner
Mean SD Mean SD
Age (years)
b 31.6 6.6 28.9 7.6
Range 19.9–43.5 19.8–44.7
Duration relationship (years) 5.7 6.3
Range 1–22
Education level 3.6 1.4 4.0 1.6
N% N%
Employment status
b
Employed for wages 18 95 11 58
Student 1 5 4 21
Housewife 4 21
Children
Yes 5 26
No 14 74
RRRTM +
Yes 11 58
No 8 42
RRRTM Resection of residual retroperitoneal tumor mass
ap<0.01
bp<0.05
282reference groups at T1, and patients (t=2.2, p<0.05)
reported worse mental health at T1. At T2, patients
reported worse physical functioning than the reference
group of men (t=2.6, p<0.02) but partners reported better
physical functioning than the reference group of women (t=
−2.2, p<0.05). Patients also reported worse social function-
ing than the reference men at T2 (t=3.3, p<0.01). No
differences were found between the patients’ and partners’
mental health and the norm groups at T2. Only one
significant difference was found at T3: Patients reported
better physical functioning than men in the reference group
(t=−2.6, p<0.02) (Table 2).
Discussion
The present study was the first to prospectively and
longitudinally examine psychosocial functioning in both
testicular cancer patients and their partners. We focused on
SRS and QoL (physical functioning, social functioning,
and mental health) after orchiectomy but before the start of
chemotherapy, immediately after completion of chemo-
therapy, and 9 months later (1 year follow-up).
SRS in couples were most salient before the start of
chemotherapy. Twenty-six percent of patients reported
clinically elevated SRS at this time, a number comparable
to the 30% of patients with clinically elevated distress
found in a recent study on testicular cancer patients [23]. A
review of stress response syndromes in adult cancer
populations showed that the incidence of clinically
elevated SRS ranged from 3 to 4% in patients recently
diagnosed with early stage cancer [34]. The majority of
these studies used the same questionnaire for measuring
SRS as we did. The same review identified younger age,
greater proximity to diagnosis, more advanced disease, and
greater treatment intensity as risk factors for a higher level
of SRS. The much higher percentage found in our study at
the first measurement time may be explained by the
prevalence of these four risk factors in our patient group.
Not only did patients appear distressed, but also almost
twice as many of the partners compared to patients reported
clinically elevated levels of SRS. Female sex was found to
correlate with greater stress response symptomatology in
cancer populations [34]. Of course, these spouses are not
patients themselves, but they obviously face cancer-related
fears and worries as well. Our results affirm earlier findings
that female spouses of cancer patients are vulnerable to
distress, and often report higher levels of distress compared
to their male counterparts [20, 21, 40–42]. It was also
found that partners who had children experienced more
SRS a year after diagnosis compared to partners without
children. This higher level of distress might also be a result
of caregiving tasks that are often the domain of female
partners.
SRS in couples decreased after completion of chemo-
therapy. One year after diagnosis, stress response levels in
patients rose slightly, but they continued to decrease in
partners. These patterns suggest that the period before
chemotherapy commences is most stressful, and that
recovery seems to occur within a year. At the time of the
first measurement the responses of the couples seem to be
colored by the fact that they had recently learned the
diagnosis, and the outcome of treatment remained
uncertain. Concerns of couples about side effects of
chemotherapy such as nausea, the possibility of immuno-
deficiency, and hair loss may contribute to distress.
Partners also have caregiving tasks that can exacerbate
their distress [22]. All couples in this study received
Table 2 SRS and QoL of patients and partners
T1 T2 T3 Reference group Repeated
measures
ANOVA
T1–T2 T2–T3 T1–T3
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Fp rp rp rp
Stress response symptoms Patient 18.1 (13.0) 10.2 (10.7) 12.3 (9.9) 7.9 0.012 0.65 0.002 0.71 0.001 0.70 0.001
Partner 25.8 (9.3) 15.2 (12.6) 12.1 (12.4) 17.7 0.001 0.41 ns 0.64 0.003 0.16 ns
Physical functioning Patient 93.4 (10.8) 70.5 (23.4) 92.6 (13.3) 84.5 (22.3)
a,b,c 21.4 0.001 0.28 ns 0.38 ns 0.20 ns
Partner 90.2 (19.0) 90.8 (19.0) 89.7 (19.9) 80.7 (23.6)
b,d 0.19 ns 0.79 0.001 0.80 0.001 0.97 0.001
Social functioning Patient 77.6 (19.7) 71.1 (22.8) 90.8 (13.1) 88.4 (19.6)
d,e 9.0 0.008 0.61 0.009 0.19 ns 0.17 ns
Partner 72.1 (20.2) 77.6 (20.7)
f 84.5 (16.5) 86.1 (20.9)
a 12.9 0.002 0.60 0.007 0.37 ns 0.68 0.001
Mental health Patient 68.2 (22.3) 77.5 (11.9) 81.9 (13.4) 79.4 (17.3)
d 6.7 0.019 0.55 0.017 0.33 ns 0.23 ns
Partner 69.1 (13.6) 71.2 (15.6) 74.3 (15.1) 75.5 (18.9) 2.6 ns 0.72 0.001 0.64 0.004 0.52 0.023
ap<0.01 (independent t test T1 and reference group)
bp<0.05 (independent t test T2 and reference group)
cp<0.05 (independent t test T3 and reference group)
dp<0.05 (independent t test T1 and reference group)
ep<0.01 (independent t test T2 and reference group)
fp<0.01 (Wilcoxon test patients and spouses)
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after diagnosis none of the patients had experienced a
relapse of disease. Couples seemed to have recovered from
this major life event over the year, possibly as a
consequence of the success of treatment reducing insecuri-
ty about outcome.
An interesting finding was that before commencement of
chemotherapy, the level of SRS of patient and partner was
inversely related. When one spouse was reporting more
SRS, the other reported less. This might be a psychological
mechanism through which spouses want to protect one
another fromtheir own distress, a finding reported before in
studies on couples facing cancer [40]. Another possible
interpretation might be that patients who expressed very
low levels of distress were using denial, avoidance, or other
repressive psychological mechanisms while their partners
carried the psychological burden of stress. A patient who
expresses high distress may also allow his spouse to
assume a stronger supportive role, and thus reduce her
expression of stress.
In line with the medical trajectory, physical functioning
of patients was worst after completion of chemotherapy. As
a consequence of chemotherapy, many patients still
experience adverse side effects, including fatigue and a
sense of physical exhaustion. It is surprising to note that
physical functioning of patients was better than that of the
reference group before start of chemotherapy and 1 year
later. The first measurement occurred shortly after removal
of the affected testicle, and patients may have experienced
physical relief after the initiation of treatment. It may also
be that age contributed to the difference found between the
patient group and the reference group. Younger age is
associated with better physical functioning [39], and the
mean age of the patients in this study was somewhat more
than 10 years lower than that of the reference group. There
may have been other differences from the reference group
as well, such as physical activity and SES. Partners’
physical functioning did not change over the year but they
also experienced better physical functioning than the
reference group before and after chemotherapy. In an
earlier cross-sectional study we found that partners of men
who survived testicular cancer between 1–20 years re-
ported better physical functioning than a reference group of
women, even years after diagnosis [30]. Partners of
testicular cancer patients may have changed the evaluation
of their own health in a positive way after witnessing the
diagnosis and treatment of a life-threatening illness.
In patients, social functioning was worst immediately
after completion of chemotherapy, and in spouses before
start of chemotherapy. Before start of chemotherapy, both
partners reported worse social functioning compared to the
reference groups. Before chemotherapy starts, couples are
probably overwhelmed by the implications of a cancer
diagnosis and focus more on the treatment to come rather
than on being socially active as usual. As a consequence of
chemotherapy, patients may still suffer from negative side
effects like fatigue and impaired physical functioning,
which in turn may affect their social functioning. Social
functioning in patients and partners was positively related
after completion of chemotherapy, meaning that when one
partner experienced better social functioning the other also
did. Couples had comparable social functioning to that of
the reference groups 1 year after diagnosis; they seem to
have returned to their usual social activities. This finding
is in line with studies on testicular cancer survivors that
show little or no change in social contacts and work
activities [6, 43].
Mental health of patients improved over the year. It was
poorer than that of men in the reference group but only
before start of chemotherapy. Mental health of partners was
comparable throughout the year and to that of a reference
group of women, despite the high level of SRS they
reported before start of chemotherapy. SRS apparently are
a different expression of mental functioning and may be
encapsulated or separated out.
It appeared that functioning in couples facing testicular
cancer was not similar in patients and partners. Testicular
cancer patients showed u-shaped trajectories of SRS,
physical functioning, and social functioning. This pattern
seemingly followed the medical trajectory they had
undergone and was found before in a large group of
testicular cancer patients [24]. Mental health of patients
improved over the year. Spouses reported a decline in SRS
and an improvement in social functioning, but no change in
physical functioning or mental health over the year.
Differences between patients and partners were also
noticeable in stability of functioning. In patients, earlier
levels of SRS were strongly predictive of later levels while
less individual stability was found with regard to physical
and social functioning and to mental health. Partners
reported less individual stability in SRS over time,
although individual stability was found between T2 and
T3. However, partners were individually highly consistent
in their reports of physical functioning and somewhat less
strong in mental health and social functioning. In addition,
correlations between the functioning of patients and
partners were moderate to very low. We also found that
at the second and third measurement time, there were no
couples in which both the patient and the partner reported
clinically elevated levels of SRS. This finding confirms the
lack of correspondence in functioning between patient and
partner.
Thesefindingssupportrecentstudies thatfounddifferent
adjustment patterns for patients and partners, and a lack of
correspondence in functioning [19, 20]. Research is needed
to examine if these different reaction patterns to a cancer
diagnosis affect the marital relationship.
This study has some limitations. First, the possibility of
including couples was limited because testicular cancer has
a low incidence, and because of the young age of patients at
diagnosis, part of this group will not yet have established a
steady relationship. Second, no information was available
284on the functioning of couples who declined to participate.
They may have been those who were functioning best or
worst, thus biasing the results in either direction. Third,
because of the limited sample size, variables that measure
more in depth relationship aspects like marital satisfaction
were not included in this study. In a previous retrospective
study on testicular cancer, factors identified as important
for couple adjustment like good communication, spousal
support, and marital satisfaction all appeared to facilitate
better functioning [32]. These moderating factors in
adjustment of both patient and spouse deserve to be
studied prospectively in the future.
In summary, this study was the first longitudinal
prospective exploration of functioning in couples facing
testicular cancer during the first year after the diagnosis.
Patients confronted with disseminated testicular cancer and
their partners reacted differently to this stressor. Clinically
elevated stress response levels were present in one third of
patients and half of the partners before start of chemother-
apy. Patients reported worst mental health before start of
chemotherapy, and worst physical and social functioning
immediately after completion of chemotherapy. Partners
reported an improvement in social functioning, and no
change in physical functioning and mental health over the
year. QoL of patients and partners was comparable to that
of the reference groups a year after start of chemotherapy,
patients even reported better physical functioning at that
time. These findings support earlier retrospective studies in
testicular cancer survivors and their spouses that also
reported few long-term effects in psychosocial functioning
in the group overall, but that identified a small group that
remains distressed [16, 31, 32]. Little correspondence was
found in the functioning of the partners. Findings should be
regarded as preliminary, as the study sample was limited in
size. However, clinicians can be reassured that the effect of
disseminated testicular cancer on the QoL of patients and
their partners seems to be temporary, although a minority
does seem to need clinical attention for SRS.
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